Peripheral vasodilation initiates the hyperdynamic circulation in cirrhosis. Somatostatin and its analogues, such as octreotide, have a vasoconstrictive effect in cirrhotic patients and experimental animals with portal hypertension. The exact mechanism of octreotide-induced vasoconstriction remains
Cardiovascular effects of octreotide in patients with hepatic cirrhosis
β Scribed by P. Aiden McCormick; Jason Chin; Lynda Greenslade; Stelios Karatapanis; Robert Dick; Neil McIntyre; Andrew K. Burroughs
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 679 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Octreotide is thought to reduce splanchnic and variceal blood flow with minimal effects on the systemic circulation in cirrhotic patients with portal hypertension. However, we noticed significant bradycardia in some patients immediately after administration of bolus doses of octreotide. Therefore, we investigated the effect of intravenous octreotide on systemic hemodynamics in 59 patients with cirrhosis. In two double-blind, placebocontrolled protocols, 32 patients received a 25-pg bolus and 20 patients received an infusion of 50-pg/hr of octreotidelplacebo. Immediately after the bolus dose of octreotide was administered, there were significant reductions in pulse rate (77 % 3 vs. 65 2 3 beats per minute, P < .01) and cardiac output (9.2 ? 0.8 vs. 7.9 i 0.8 Umin; P < .01) and significant increases in mean arterial pressure (81 +-3 vs. 87 r 3 mm Hg; P < .05), mean pulmonary artery pressure (9.1 -t 1.0 vs. 16.6 t 1.5 mm Hg; P < .Ol), right atrial pressure (3.8 2 0.8 vs. 6.6 2 1.0 mm Hg; P < .Ol), right ventricular pressure (7.1 ? 0.6 vs. 12.5 2 1.3 mm Hg; P <: .Ol), pulmonary capillary wedge pressure (4.8 ? 0.8 vs. 11.2 & 1.4 mm Hg; P < .Ol), systemic vascular resistance, and pulmonary vascular resistance. Thirty minutes after the start of the infusion, there were significant increases in mean right atrial pressure, right ventricular pressure, pulmonary artery pressure, and pulmonary capillary wedge pressure. This study suggests that intravenous octreotide has significant effects on the systemic circulation in patients with cirrhosis and that these effects appear to be more marked after administration of bolus doses. (HEPATOLOGY 1995;
π SIMILAR VOLUMES
The pharmacokinetics of metoclopramide has been studied after acute IV administration to 12 patients with hepatic cirrhosis (6 with and 6 without ascites) and 6 control subjects. The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respe
The management of both compensated and decompensated progressed to cirrhosis is estimated to be 20% to 30%. 1 In addition to patients who present with symptoms or signs cirrhosis caused by hepatitis C must be viewed in the context of the natural history of the disease. The prognosis of compen-of chr
Prostaglandins of the E (PGE) series have long been considered ''catabolic'' hormones, but recent data suggest that they may be secreted in critically ill patients to counteract stress hormones, stimulating protein synthesis. Their use is under scrutiny to improve hepatic microcirculation and as cyt